Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that , founder and chief executive officer of Crinetics, will present at the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 8-11, 2024.
Details of the corporate presentation are as follows:
Date: | Tuesday, January 9, 2024 |
Time: | 3:45 p.m. Pacific Time |
Room: | Borgia Room |
The live and archived webcast will be accessible on the page in the Investors section on the Crinetics’ website at .
If you are interested in arranging a 1×1 meeting with management, please contact your J.P. Morgan representative.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. , an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for , a first-in-class, investigational, oral ACTH antagonist, that is currently in Phase 2 clinical studies for the treatment of Cushing’s disease and congenital adrenal hyperplasia. All of the company’s are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, hyperinsulinism, diabetes and obesity.
Investors:
Chas Schultz
VP, Investor Relations
(858) 450-6464
Corey Davis
LifeSci Advisors
(212) 915-2577
Media:
Natalie Badillo
Head of Corporate Communications
(858) 450-6464